AgeneBio

AgeneBio, Inc. is a small pharmaceutical company based in Baltimore, Maryland. With a team of five employees, AgeneBio has generated \$2.5 million in revenue. AgeneBio is focused on developing innovative therapeutics aimed at preventing neurodegeneration and preserving cognitive function. Their target patients include those struggling with amnestic mild cognitive impairment (aMCI), the pre-dementia stage of Alzheimer's disease, as well as individuals with various neurological and psychiatric diseases. The company's therapies are built upon decades of research at Johns Hopkins University and leading research centers globally. Their lead candidate, AGB101, is currently in Phase 3 and, if approved, would be the first therapeutic targeting hippocampal overactivity, potentially slowing the progression to Alzheimer's dementia. AgeneBio also has a novel GABA-A alpha5 small molecule program in late discovery stages, showing promise for treating a range of conditions like aMCI, autism, and schizophrenia. For more information, visit AgeneBio's website at agenebio.com or follow them on Twitter @AgeneBio.